This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.
Aged ≥18 years , regardless of gender.
Diagnosed with primary aldosteronism (PA).
Mean seated office systolic blood pressure (msSBP) ≥145 mmHg.
Receiving stable background antihypertensive therapy.
Mean seated office systolic blood pressure (msSBP) ≥180 mmHg and/or mean seated office diastolic blood pressure (msDBP) ≥110 mmHg.
History or diagnosis of malignant hypertension, hypertensive emergency, hypertensive crisis or hypertensive encephalopathy.
History or diagnostic evidence of other secondary hypertension.
Prior surgical resection for adrenal adenoma.
Parallel
SAL0140 Tablets
DrugDrug: SAL0140 Tablets
SAL0140 Tablets
DrugSAL0140 Tablets
SAL0140 placebo
DrugPlacebo
The baseline change in mean seated systolic blood pressure (msSBP)
Change from baseline in mean seated systolic blood pressure (msSBP) after 12 weeks of randomized, double-blind treatment
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
